Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

European Journal of Endocrinology, Vol 132, Issue 1, 86-87
Copyright © 1995 by European Society of Endocrinology
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wesche, M.
Right arrow Articles by Wiersinga, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wesche, M.
Right arrow Articles by Wiersinga, W.
Articles

Reduction in goiter size by 131I therapy in patients with non-toxic multinodular goiter

MF Wesche, MM Tiel-v-Buul, NJ Smits, and WM Wiersinga

Department of Internal Medicine (Division of Endocrinology), University of Amsterdam, The Netherlands.

A retrospective follow-up study of 131I treatment was performed in 10 females (median age 48 years, range 40-74 years) with non-toxic multinodular goiter. The median dose of 131I given was 20 mCi (range 14-65 mCi). Thyroid volume was measured by ultrasonography. The median follow-up period was 26 months (range 12-68 months). Nine patients had a reduction of goiter size: thyroid volume decreased from 88 +/- 14.9 ml (mean +/- SEM) to 49 +/- 10.9 ml 1 year after 131I treatment. The relative decrease of goiter size was 48% after 1 year (N = 9) and 59% after 2 years (N = 5). One patient did not respond and was referred for operation. Side effects were mild spontaneously resolving radiation thyroiditis in one patient and subclinical hypothroidism in four patients. In conclusion, 131I treatment of non-toxic goiter is an effective treatment at the expense of post-radiation (subclinical) hypothyroidism.


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
T. Watt, M. Groenvold, A. K. Rasmussen, S. J. Bonnema, L. Hegedus, J. B. Bjorner, and U. Feldt-Rasmussen
Quality of life in patients with benign thyroid disorders. A review.
Eur. J. Endocrinol., April 1, 2006; 154(4): 501 - 510.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
O. Cohen, J. Ilany, C. Hoffman, D. Olchovsky, S. Dabhi, A. Karasik, E. Goshen, G. Rotenberg, and S T. Zwas
Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients
Eur. J. Endocrinol., February 1, 2006; 154(2): 243 - 252.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W.-A. Nieuwlaat, A. R. Hermus, H. A. Ross, W. C. Buijs, M. A. Edelbroek, J. W. Bus, F. H. Corstens, and D. A. Huysmans
Dosimetry of Radioiodine Therapy in Patients with Nodular Goiter After Pretreatment with a Single, Low Dose of Recombinant Human Thyroid-Stimulating Hormone
J. Nucl. Med., April 1, 2004; 45(4): 626 - 633.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W.-A. Nieuwlaat, D. A. Huysmans, H. C. van den Bosch, C. G. (F. Sweep, H. A. Ross, F. H. Corstens, and A. R. Hermus
Pretreatment with a Single, Low Dose of Recombinant Human Thyrotropin Allows Dose Reduction of Radioiodine Therapy in Patients with Nodular Goiter
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3121 - 3129.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. Hegedus, S. J. Bonnema, and F. N. Bennedbaek
Management of Simple Nodular Goiter: Current Status and Future Perspectives
Endocr. Rev., February 1, 2003; 24(1): 102 - 132.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W.-A. Nieuwlaat, A. R. Hermus, F. Sivro-Prndelj, F. H. Corstens, and D. A. Huysmans
Pretreatment with Recombinant Human TSH Changes the Regional Distribution of Radioiodine on Thyroid Scintigrams of Nodular Goiters
J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5330 - 5336.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. H. Samuels
Editorial: Evaluation and Treatment of Sporadic Nontoxic Goiter--Some Answers and More Questions
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 994 - 997.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. F. T. Wesche, M. M. C. Tiel-v Buul, P. Lips, N. J. Smits, and W. M. Wiersinga
A Randomized Trial Comparing Levothyroxine with Radioactive Iodine in the Treatment of Sporadic Nontoxic Goiter
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 998 - 1005.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. A. Huysmans, W.-A. Nieuwlaat, R. J. Erdtsieck, A. P. Schellekens, J. W. Bus, B. Bravenboer, and A. R. Hermus
Administration of a Single Low Dose of Recombinant Human Thyrotropin Significantly Enhances Thyroid Radioiodide Uptake in Nontoxic Nodular Goiter
J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3592 - 3596.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. J. Bonnema, H. Bertelsen, J. Mortensen, P. B. Andersen, D. U. Knudsen, L. Bastholt, and L. Hegedus
The Feasibility of High Dose Iodine 131 Treatment as an Alternative to Surgery in Patients with a Very Large Goiter: Effect on Thyroid Function and Size and Pulmonary Function
J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3636 - 3641.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. R. Hermus and D. A. Huysmans
Treatment of Benign Nodular Thyroid Disease
N. Engl. J. Med., May 14, 1998; 338(20): 1438 - 1447.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. Nygaard, J. H. Knudsen, L. Hegedus, A. V. C. Scient, and J. E. Molholm Hansen
Thyrotropin Receptor Antibodies and Graves' Disease, a Side-Effect of 131I Treatment in Patients with Nontoxic Goiter
J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2926 - 2930.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 European Society of Endocrinology.